Metabolism of MK-0524, a Prostaglandin D2 Receptor 1 Antagonist, in Microsomes and Hepatocytes from Preclinical Species and Humans

No abstract is available for this paper.

• Publication year

  2007

• Venue

  Drug Metabolism And Disposition

• Publication date

  2007-02-01

• Fields of study

  Biology, Medicine, Chemistry

• Identifiers
  DOI 10.1124/dmd.106.011551PMID 17132765
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Discovery of a potent and selective prostaglandin D2 receptor antagonist, [(3R)-4-(4-chloro-benzyl)-7-fluoro-5-(methylsulfonyl)-1,2,3,4-tetrahydrocyclopenta[b]indol-3-yl]-acetic acid (MK-0524).

  2007cited by this paper
• In vitro biotransformations of the prostaglandin D2 (DP) antagonist MK-0524 and synthesis of metabolites.

  2007cited by this paper
• The pharmacokinetics and disposition of MK-0524, a Prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys

  2007cited by this paper
• Evaluation of the safety and tolerability of prolonged-release nicotinic acid in a usual care setting: the NAUTILUS study

  2006cited by this paper
• Antagonism of the prostaglandin D2 receptor 1 suppresses nicotinic acid-induced vasodilation in mice and humans.

  2006cited by this paper
• Safety and tolerability of simvastatin plus niacin in patients with coronary artery disease and low high-density lipoprotein cholesterol (The HDL Atherosclerosis Treatment Study).

  2004cited by this paper
• Safety and compliance with once-daily niacin extended-release/lovastatin as initial therapy in the Impact of Medical Subspecialty on Patient Compliance to Treatment (IMPACT) study.

  2004cited by this paper
• Characterization of rat and human UDP-glucuronosyltransferases responsible for the in vitro glucuronidation of diclofenac.

  2001cited by this paper
• Glucuronidation of 1-hydroxypyrene by human liver microsomes and human UDP-glucuronosyltransferases UGT1A6, UGT1A7, and UGT1A9: development of a high-sensitivity glucuronidation assay for human tissue.

  2001influential reference
• Drug treatment of lipid disorders.

  1999cited by this paper
• Drug treatment of lipid disorders.

  1999cited by this paper
• Human UGT2B7 catalyzes morphine glucuronidation.

  1997influential reference
• Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation.

  1995influential reference
• Bilirubin UDP-glucuronosyltransferase 1 is the only relevant bilirubin glucuronidating isoform in man.

  1994influential reference
• Complementary deoxyribonucleic acid cloning and expression of a human liver uridine diphosphate-glucuronosyltransferase glucuronidating carboxylic acid-containing drugs.

  1993cited by this paper
• Validation and use of cloned, expressed human drug-metabolizing enzymes in heterologous cells for analysis of drug metabolism and drug-drug interactions.

  1993cited by this paper
• Identification of skin as a major site of prostaglandin D2 release following oral administration of niacin in humans.

  1992cited by this paper
• Improvement of the nicotinic acid test in the diagnosis of Gilbert's syndrome by pretreatment with indomethacin.

  1985cited by this paper
• Effects of nicotinic acid therapy on plasma high density lipoprotein subfraction distribution and composition and on apolipoprotein A metabolism.

  1979cited by this paper
• Prostaglandins contribute to the vasodilation induced by nicotinic acid.

  1979cited by this paper

• Evaluating the absence of allometric scaling for hepatic microsomal Phase I and Phase II xenobiotic biotransformation among mammals.

  2025cites this paper
• Indole-Based and Cyclopentenylindole-Based Analogues Containing Fluorine Group as Potential 18F-Labeled Positron Emission Tomography (PET) G-Protein Coupled Receptor 44 (GPR44) Tracers

  2023cites this paper
• Estimation of fraction of drug metabolism by a single UDP‐glucuronosyl transferase enzyme using relative expression factor

  2022cites this paper
• PPM1A Phosphatase is Involved in Regulating Pregnane Xenobiotic Receptor Mediated Cytochrome P450 3A4 Gene Expression

  2014cites this paper
• Xenobiotic–urea conjugates; chemical or biological?

  2014cites this paper
• Using human recombinant UDP-glucuronosyltransferase isoforms and a relative activity factor approach to model total body clearance of laropiprant (MK-0524) in humans

  2013influential citation
• NIACIN AND NIACIN / LAROPIPRANT COMBINATION: OPENING NEW HOPES FOR DYSLIPIDEMIA AND CARDIOVASCULAR DISEASES WITH FEW NOVEL ACTIONS

  2013cites this paper
• Bioactivation I: Bioactivation by Cytochrome P450s

  2012cites this paper
• Radiolabeled absorption, distribution, metabolism, and excretion studies in drug development: why, when, and how?

  2012cites this paper
• In vitro bioactivation of bazedoxifene and 2-(4-hydroxyphenyl)-3-methyl-1H-indol-5-ol in human liver microsomes.

  2012cites this paper
• Novel Pleiotropic Effects of Niacin

  2012cites this paper
• Pathways of Reactive Metabolite Formation with Toxicophores/‐Structural Alerts

  2012cites this paper
• Emerging drugs for coronary artery disease. From past achievements and current needs to clinical promises

  2011cites this paper
• Pharmacokinetics and Metabolism in Rats, Dogs, and Monkeys of the Cathepsin K Inhibitor Odanacatib: Demethylation of a Methylsulfonyl Moiety as a Major Metabolic Pathway

  2011cites this paper
• Pharmacokinetics of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, in Patients With Moderate Hepatic Impairment

  2011influential citation
• In vitro and in vivo small intestinal metabolism of CYP3A and UGT substrates in preclinical animals species and humans: species differences

  2011cites this paper
• Effects of multiple doses of clarithromycin on the pharmacokinetics of laropiprant in healthy subjects.

  2011cites this paper
• Future of GPR109A agonists in the treatment of dyslipidaemia

  2011cites this paper
• Tarek Ahmed bw.indd

  2011cites this paper
• Effects of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Steady‐State Pharmacokinetics of Digoxin in Healthy Adult Subjects

  2010cites this paper
• Influence of Laropiprant, a Selective Prostaglandin D2 Receptor 1 Antagonist, on the Pharmacokinetics and Pharmacodynamics of Warfarin

  2009influential citation
• Review of extended-release niacin/laropiprant fixed combination in the treatment of mixed dyslipidemia and primary hypercholesterolemia

  2009cites this paper
• Pharmacokinetics of Laropiprant and Glucuronide Metabolite in Patients with Severe Renal Insufficiency

  2009cites this paper
• Effect of Laropiprant, a PGD2 Receptor 1 Antagonist, on Estradiol and Norgestimate Pharmacokinetics After Oral Contraceptive Administration in Women

  2009cites this paper
• Pharmacokinetics, Pharmacodynamics, and Safety of a Prostaglandin D2 Receptor Antagonist

  2008cites this paper
• Metabolic activation of a novel 3-substituted indole-containing TNF-alpha inhibitor: dehydrogenation and inactivation of CYP3A4.

  2008cites this paper
• The pharmacokinetics and disposition of MK-0524, a Prostaglandin D2 receptor 1 antagonist, in rats, dogs and monkeys

  2007cites this paper
• RECEPTOR ANTAGONIST, IN HUMANS

  2007cites this paper
• Metabolic activation of indole-containing prostaglandin D2 receptor 1 antagonists: impacts of glutathione trapping and glucuronide conjugation on covalent binding.

  2007cites this paper
• Absorption, Metabolism, and Excretion of [14C]MK-0524, a Prostaglandin D2 Receptor Antagonist, in Humans

  2007cites this paper
• Vascular Health and Risk Management Dovepress Open Access to Scientific and Medical Research Open Access Full Text Article Review of Extended-release Niacin/laropiprant Fixed Combination in the Treatment of Mixed Dyslipidemia and Primary Hypercholesterolemia

  year unknowncites this paper